Search results for "Adrenergic"

showing 3 items of 433 documents

An arthritogenic alphavirus uses the α1β1 integrin collagen receptor

2005

Ross River (RR) virus is an alphavirus endemic to Australia and New Guinea and is the aetiological agent of epidemic polyarthritis or RR virus disease. Here we provide evidence that RR virus uses the collagen-binding alpha1beta1 integrin as a cellular receptor. Infection could be inhibited by collagen IV and antibodies specific for the beta1 and alpha1 integrin proteins, and fibroblasts from alpha1-integrin-/- mice were less efficiently infected than wild-type fibroblasts. Soluble alpha1beta1 integrin bound immobilized RR virus, and peptides representing the alpha1beta1 integrin binding-site on collagen IV inhibited virus binding to cells. We speculate that two highly conserved regions with…

α1β1 integrinCollagen Type IVIntegrin alpha1IntegrinAlphavirusBiologyVirus ReplicationAntibodiesVirusIntegrin alpha1beta1Collagen receptorMiceRoss River virusVirologyRoss River virusAnimalsHumansMice KnockoutCollagen IVVirus receptorFibroblastsbiology.organism_classificationMolecular biologySolubilityIntegrin alpha Mbiology.proteinReceptors VirusIntegrin beta 6Receptors Adrenergic beta-1ReceptorHeLa CellsVirology
researchProduct

NT-3 in cardiovascular pathologies

2019

La NT-3 y su receptor TrkC son puntos clave en la formación del corazón y los vasos durante la etapa embrionaria. Sin embargo, el papel de la NT-3 como modulador de las funciones cardiovasculares en la edad adulta no ha sido investigado con detalle. El objetivo de la presente Tesis es determinar la expresión de NT-3 y TrkC en el sistema cardiovascular humano y de roedores, así como el papel de la vía NT-3/TrkC como moduladora de las funciones cardiovasculares y su relación con las enfermedades a este nivel. Para ello, se cuantificó la expresión génica y proteica de NT-3 y TrkC, en tejidos humanos y de roedores, así como en células humanas cardiacas y aorticas. Los resultados muestran que lo…

β-adrenergic receptorvesselsNT-3UNESCO::CIENCIAS MÉDICASTrkCUNESCO::CIENCIAS DE LA VIDAheart failure:CIENCIAS MÉDICAS [UNESCO]:CIENCIAS DE LA VIDA [UNESCO]
researchProduct

Monotherapy with indacaterol once daily reduces the rate of exacerbations in patients with moderate-to-severe COPD: Post-hoc pooled analysis of 6 mon…

2014

Summary Background In patients with COPD, exacerbations are associated with poor quality of life and may shorten survival. Prevention of exacerbations is, therefore, a key objective in COPD management. Indacaterol, a once-daily ultra-long-acting β 2 -agonist, has been shown to reduce exacerbations in various studies. This pooled analysis evaluated the effect of indacaterol on exacerbations versus placebo. Methods Six-month data were pooled from three randomized, double-blind, and placebo-controlled studies: indacaterol 300 μg versus placebo (1 year); indacaterol 150 μg and 300 μg versus placebo (6 months); and indacaterol 150 μg versus placebo (6 months). All treatments were administered on…

β2-agonistPulmonary and Respiratory Medicinemedicine.medical_specialtyExacerbationKaplan-Meier EstimateQuinolonesPlaceboDrug Administration SchedulePooled analysisExacerbationsPulmonary Disease Chronic ObstructiveFEV1/FVC ratioDouble-Blind MethodForced Expiratory VolumeInternal medicineHumansCOPDMedicineAdrenergic beta-2 Receptor AgonistsRandomized Controlled Trials as TopicIndacaterolCOPDDose-Response Relationship Drugbusiness.industryMinimal clinically important differenceHazard ratiomedicine.diseaseConfidence intervalBronchodilator AgentsClinical Trials Phase III as TopicAnesthesiaIndansIndacaterolbusinessBronchodilatormedicine.drugRespiratory Medicine
researchProduct